-- BV Market Projected to Reach $1.0 Billion in the U.S. by 2033 -- -- BV Affects 21 Million U.S. Women; As many as 50% Experience Recurrent BV Within Six Months of Treatment -- SAN DIEGO, June 11, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) today...
Hence then, the article about notable data on evofem s solosec in recurrent bacterial vaginosis bv released at acog annual meeting was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting )
Also on site :
- ‘The Comeback’ took on Hollywood long before ‘The Studio.’ Now, Valerie Cherish will have her curtain call
- ‘Project Hail Mary’ Answers Prayers: Best Opening For MPA Movie YTD With Near $141M WW — Global B.O. Update
- An exclusive tour of Amazon’s Trainium lab, the chip that’s won over Anthropic, OpenAI, even Apple